order
gain
entri
cell
divers
virus
includ
ebola
viru
sarscoronaviru
emerg
merscoronaviru
depend
activ
envelop
glycoprotein
host
cell
proteas
respect
enzym
thu
excel
target
antivir
intervent
cell
cultur
activ
ebola
viru
well
sarsand
merscoronaviru
accomplish
endosom
cystein
proteas
cathepsin
l
ctsl
cathepsin
b
ctsb
addit
sarsand
merscoronaviru
use
serin
proteas
local
cell
surfac
activ
howev
current
unclear
proteas
facilit
viral
spread
infect
host
report
cystein
proteas
inhibitor
amino
closelyrel
vinylsulfon
act
broadspectrum
antivir
target
cathepsinmedi
cell
entri
alreadi
advanc
stage
develop
number
parasit
diseas
chaga
diseas
proven
safe
effect
rang
anim
model
inhibit
sarscov
ebola
viru
entri
observ
subnanomolar
rang
order
assess
whether
cystein
serin
proteas
promot
viral
spread
host
compar
antivir
activ
optim
camostat
inhibitor
relat
serin
proteas
employ
pathogen
anim
model
sarscov
infect
demonstr
viral
spread
pathogenesi
sarscov
driven
serin
rather
cystein
proteas
effect
prevent
camostat
camostat
clinic
use
treat
chronic
pancreat
thu
repres
excit
potenti
therapeut
respiratori
coronaviru
infect
result
indic
camostat
similar
serin
proteas
inhibitor
might
effect
option
treatment
sar
potenti
mer
vinyl
sulfonebas
inhibitor
excel
lead
candid
ebola
viru
therapeut
publish
elsevi
bv
order
gain
entri
cell
divers
virus
includ
ebola
viru
sarscoronaviru
emerg
merscoronaviru
depend
activ
envelop
glycoprotein
host
cell
proteas
respect
enzym
thu
excel
target
antivir
intervent
cell
cultur
activ
ebola
viru
well
sarsand
merscoronaviru
accomplish
endosom
cystein
proteas
cathepsin
l
ctsl
cathepsin
b
ctsb
addit
sarsand
merscoronaviru
use
serin
proteas
local
cell
surfac
activ
howev
current
unclear
proteas
facilit
viral
spread
infect
host
report
cystein
proteas
inhibitor
n
benzenesulfonyl
e
amino
closelyrel
vinylsulfon
act
broadspectrum
antivir
target
cathepsinmedi
cell
entri
alreadi
advanc
stage
develop
number
parasit
diseas
chaga
diseas
proven
safe
effect
rang
anim
model
inhibit
sarscov
ebola
viru
entri
observ
subnanomolar
rang
order
assess
whether
cystein
serin
proteas
promot
viral
spread
host
compar
antivir
activ
optim
camostat
inhibitor
relat
serin
proteas
employ
pathogen
anim
model
sarscov
infect
demonstr
viral
spread
pathogenesi
sarscov
driven
serin
rather
cystein
proteas
effect
prevent
camostat
camostat
clinic
use
treat
chronic
pancreat
thu
repres
excit
potenti
therapeut
respiratori
coronaviru
infect
result
indic
camostat
similar
serin
proteas
inhibitor
might
effect
option
treatment
sar
potenti
mer
vinyl
sulfonebas
inhibitor
excel
lead
candid
ebola
viru
therapeut
publish
elsevi
bv
emerg
viral
diseas
pose
uniqu
risk
public
health
ebola
viru
sever
acut
respiratori
syndrom
coronaviru
sarscov
member
henipaviru
genu
paramyxovirus
highli
pathogen
virus
arisen
past
year
caus
threaten
caus
major
outbreak
new
viral
threat
continu
emerg
recent
demonstr
novel
betacoronaviru
middl
east
respiratori
syndrom
coronaviru
merscov
identifi
zaki
et
al
memish
et
al
de
groot
et
al
current
approv
vaccin
therapeut
mani
highli
pathogen
virus
potenti
depend
cathepsin
includ
ebola
viru
nipah
viru
niv
merscov
sarscov
broadspectrum
antivir
drug
overlap
therapeut
indic
would
facilit
rapid
respons
new
chang
pandem
threat
potenti
even
without
precis
identif
agent
target
host
factor
involv
viral
entri
provid
excel
avenu
drug
develop
due
limit
number
pathway
involv
glycoprotein
corona
filoand
paramyxovirus
facilit
viral
entri
target
cell
bind
receptor
drive
fusion
viral
host
cell
membran
howev
glycoprotein
synthes
inact
precursor
depend
activ
host
cell
proteas
acquir
fusion
activ
form
consequ
respect
enzym
potenti
target
broadspectrum
antivir
intervent
cell
cultur
studi
demonstr
endosom
cystein
proteas
particular
cathepsin
b
ctsb
andor
l
ctsl
activ
glycoprotein
filovirus
sarscov
coronavirus
niv
hendra
hev
virus
facilit
entri
certain
cell
line
addit
activ
coronavirus
also
accomplish
serin
proteas
locat
cell
surfac
secret
extracellular
space
simmon
et
al
howev
respect
role
endosom
cell
surfac
proteas
viral
spread
infect
host
unknown
develop
proteas
inhibitor
abl
inhibit
ctsl
ctsb
relat
proteas
would
excel
start
point
develop
broadspectrum
antivir
therapi
describ
discoveri
relat
compound
broadspectrum
antivir
target
endosom
proteas
involv
viral
entri
cystein
proteas
inhibitor
block
infect
viral
entri
requir
activ
serin
proteas
case
ebolaviru
ebov
also
fulli
inhibit
coronaviru
infect
target
cell
line
lack
activ
serin
proteas
use
cell
express
cellsurfac
serin
proteas
known
activ
coronavirus
serin
proteas
inhibitor
camostat
requir
full
inhibit
thu
compound
deploy
examin
activ
pathway
predomin
vivo
camostat
display
antivir
activ
pathogen
anim
model
sarscov
infect
indic
serin
proteas
inhibitor
suitabl
treatment
sar
potenti
mer
predict
effect
relat
cystein
proteas
inhibitor
versu
ebola
viru
vivo
must
await
studi
approv
biocontain
facil
cystein
proteas
inhibitor
librari
screen
work
describ
elsewher
ang
et
al
briefli
librari
includ
electrophil
cystein
proteas
inhibitor
variou
chemotyp
glycin
nitril
ketobenzoxazol
ketooxadiazol
vinylsulfon
etc
synthes
cours
industri
drug
discoveri
program
target
human
cathepsin
palmer
et
al
palmer
et
al
palmer
et
al
rydzewski
et
al
camostat
mesyl
leupeptin
bafilomycin
ammonium
chlorid
chloroquin
purchas
sigmaaldrich
novel
deriv
synthes
accord
gener
approach
describ
previous
jaishankar
et
al
illustr
scheme
nsubstitut
piperazin
obtain
commerci
sourc
r
cyclopentyl
cyclopropylmethyl
prepar
reduct
amin
bocprotect
piperazin
follow
treatment
hcl
dioxan
two
step
find
final
coupl
carboxyl
acid
vinylsulfon
amin
best
accomplish
via
mix
anhydrid
minim
epimer
phenylalanin
side
chain
final
vinylsulfon
analog
pure
judg
lcm
analysi
character
data
final
analog
provid
human
embryon
kidney
cell
cell
clone
vero
cell
obtain
american
type
cultur
collect
atcc
cell
line
gift
apath
llc
cell
grown
dulbecco
modifi
eagl
medium
dmem
invitrogen
supplement
fb
penicillin
streptomycin
uml
stabli
express
establish
transfect
cell
invitrogen
encod
gene
select
stabl
transform
use
blasticidin
lgml
stabli
express
human
also
call
aminopeptidas
n
apn
establish
transfect
cell
invitrogen
encod
gene
select
stabl
transform
use
geneticin
mgml
express
measur
flow
cytometr
analysi
lentivir
pseudotyp
gener
two
plasmid
one
encod
envelop
second
envelopedefici
hiv
report
construct
either
lucr
e
pnlluc
connor
et
al
plasmid
encod
spike
protein
human
coronavirus
sarscov
merscov
glycoprotein
gp
filovirus
ebov
formerli
known
ebolaviru
zair
sudan
ebolaviru
sudv
tai
forest
ebolaviru
tafv
reston
ebolaviru
restv
marburg
marv
well
niv
f
g
lassa
viru
gp
vesicular
stomat
viru
vsv
g
protein
chikungunya
viru
chikv
mlv
envelop
describ
simmon
et
al
simmon
et
al
simmon
et
al
salvador
et
al
salvador
et
al
bundibugyo
ebolaviru
bebov
gp
gift
edward
wright
univers
westminst
hcv
synthes
genscript
ca
junin
viru
g
protein
gift
sean
amberg
siga
technolog
plasmid
encod
cellular
type
ii
transmembran
serin
proteas
ttsp
previous
describ
lentivir
pseudovirion
produc
essenti
previous
describ
zhou
et
al
briefli
cell
transfect
lg
viral
envelop
encod
plasmid
lg
report
backbon
per
dish
calcium
phosphat
transfect
next
day
express
induc
sodium
butyr
mm
h
wash
forti
hour
transfect
supernat
filter
lmpores
filter
frozen
viru
titrat
essenti
would
use
screen
assay
requir
virion
purifi
concentr
ultracentrifug
rpm
rotor
beckman
sucros
cushion
resuspend
hank
balanc
salt
solut
hbss
store
aliquot
pseudovirus
normal
equal
infect
transduct
target
cell
serial
dilut
stock
follow
h
later
determin
luciferas
activ
cell
lysat
accord
manufactur
instruct
promega
vsvbase
pseudotyp
bear
junin
viru
g
produc
essenti
describ
steffen
et
al
transfect
cell
lg
junin
g
plasmid
infect
cell
recombin
vsvdggfp
vsvg
progeni
vsvdggfp
june
viru
collect
titrat
use
inhibit
studi
case
niv
vsvdggfp
niv
fg
virus
produc
via
calcium
phosphat
transfect
cell
ug
niv
f
lg
niv
g
transfect
cell
left
h
initi
medium
chang
infect
recombin
vsvdggfp
vsvg
moi
five
addit
hour
media
alon
compound
interest
ad
desir
concentr
cell
incub
overnight
supernat
harvest
filter
assay
inhibit
product
entrycompet
viru
examin
target
cell
preplat
cell
well
plate
allow
attach
overnight
undilut
vsvdggfp
niv
fg
made
presenc
absenc
inhibitor
ad
cell
incub
two
day
wash
fix
paraformaldehyd
gfp
fluoresc
determin
flow
cytometri
use
becton
dickinson
lsrii
cytomet
flowjo
softwar
infect
determin
sampl
infect
pseudoviron
produc
cell
compound
exposur
highthroughput
screen
viral
entri
inhibitor
perform
plate
use
dualenvelop
pseudotyp
dep
assay
briefli
compound
control
dilut
dmem
fb
lm
dmso
transfer
white
tissu
cultur
plate
nunc
use
biomek
fxp
beckmancoult
mixtur
target
viru
eg
hivluc
sarscov
control
viru
hivren
lassa
gp
hivren
mlv
env
made
concentr
ratio
deriv
empir
give
similar
robust
level
report
express
report
viru
mix
ad
well
use
matrix
wellmat
thermo
scientif
cell
cell
per
millilit
ad
well
plate
incub
two
day
co
firefli
renilla
luciferas
report
express
determin
use
dualglo
luciferas
assay
substrat
promega
assay
dose
respons
curv
perform
white
tissu
cultur
plate
nunc
target
cell
pretreat
test
compound
inhibitor
serial
dilut
medium
follow
either
singl
viru
two
report
viru
mixtur
depend
purpos
assay
envreport
combin
revers
order
demonstr
inhibit
direct
backbon
report
enzym
rather
entri
plate
incub
two
day
co
firefli
renilla
luciferas
report
express
determin
use
dualglo
luciferas
substrat
promega
detect
firefli
luciferas
report
express
use
luciferas
substrat
promega
infect
pseudotyp
vsv
niv
fg
analyz
measur
number
gfp
express
cell
flow
cytometr
analysi
either
cell
transient
express
pretreat
serial
dilut
combin
serial
dilut
camostat
mesyl
lm
combin
serial
dilut
camostat
mesyl
lm
min
incub
infectivitynorm
pseudovirus
presenc
inhibitor
cell
cultur
co
two
day
luciferas
express
measur
antivir
replic
urbani
strain
live
sarscov
well
cytotox
select
compound
investig
use
three
vitro
assay
cytopath
effect
cpe
inhibit
assay
neutral
red
nr
uptak
assay
viru
yield
reduct
assay
describ
kumaki
et
al
cell
viabil
assay
cell
seed
black
tissu
cultur
plate
costar
treat
compound
final
concentr
dmso
quantiti
atp
present
metabol
activ
cell
determin
celltiterglo
luminesc
cell
viabil
assay
kit
promega
madison
wi
mgkg
camostat
mgkg
alon
mgkg
combin
camostat
mgkg
neg
control
water
administr
week
old
femal
balbc
mice
oral
gavag
twice
day
day
begin
h
prior
viru
exposur
ten
mice
assign
group
texa
biomed
research
institut
institut
texa
biom
anim
care
use
committe
approv
anim
protocol
live
viru
assay
perform
facil
texa
biom
use
mous
adapt
strain
sarscov
kindli
provid
ralph
baric
univers
north
carolina
mice
infect
administ
pfu
viru
intranas
instil
statist
calcul
perform
excel
microsoft
seattl
wa
compound
primari
screen
consid
inhibitori
luciferas
read
sarscov
intern
control
pseudotyp
virus
fell
predefin
cutoff
sd
ic
inhibitori
concentr
cc
cell
cytotox
concentr
valu
calcul
use
nonlinear
regress
analysi
base
sigmoid
dose
respons
equat
use
prism
graphpad
softwar
inc
appli
percent
inhibit
concentr
data
select
index
si
calcul
use
formula
si
cc
ic
recent
develop
internallycontrol
dual
viru
ht
assay
identif
inhibitor
viral
entri
use
sarscov
entri
assay
screen
librari
cystein
proteas
inhibitor
confirm
activ
human
cathepsin
unsurprisingli
larg
number
hit
identifi
upon
valid
hit
robust
activ
observ
n
benzenesulfonyl
e
amino
fig
compound
known
inhibit
cruzain
cathepsinl
like
proteas
protozoan
parasit
trypanosoma
cruzi
engel
et
al
addit
inhibit
varieti
cystein
proteas
includ
human
cathepsin
choy
et
al
cathepsinlik
proteas
sever
parasit
ndao
et
al
abdulla
et
al
determin
whether
inhibit
entri
driven
viral
envelop
protein
hivbas
pseudotyp
bear
spike
coronavirus
sarscov
merscov
glycoprotein
filovirus
ebov
sudv
tafv
restv
bebov
marv
examin
togeth
control
pseudotyp
also
test
abil
prevent
activ
henc
infect
product
vsvbase
pseudotyp
salvador
et
al
bear
niv
f
g
activ
major
envelop
virus
previous
known
requir
cathepsinmedi
proteolysi
includ
varieti
coronavirus
filovirus
especi
ebov
fig
tabl
inhibit
sarscov
pseudoviru
entri
ic
nm
fig
tabl
toxic
observ
cc
lm
data
shown
merscov
envelop
requir
higher
concentr
inhibit
like
due
less
relianc
ctsl
hofmann
et
al
nevertheless
ic
low
nm
merscov
nm
contrast
nm
inhibit
infect
mediat
envelop
glycoprotein
alphaviru
chikv
rhabdoviru
vsv
flaviviru
hcv
retrovirus
mlva
xmrv
two
arenavirus
lassa
junin
viru
coronavirus
includ
sarscov
human
coronaviru
merscov
use
two
distinct
pathway
cell
entri
endosom
pathway
spike
activ
facilit
phdepend
endosom
proteas
ctsl
ii
entri
plasma
membran
reli
spike
activ
secret
surfac
proteas
trypsin
type
ii
transmembran
serin
proteas
hat
human
airway
trypsinlik
proteas
bertram
et
al
bertram
et
al
serin
proteas
inhibitor
camostat
mesyl
camostat
inhibit
enzymat
activ
cellsurfac
proteas
involv
coronaviru
activ
kawas
et
al
therefor
assess
whether
display
antivir
activ
express
cell
incub
target
cell
camostat
combin
camostat
infect
pseudovirus
bear
alon
demonstr
inhibit
transduct
simultan
treatment
camostat
increas
inhibit
fig
left
panel
similar
inhibit
pattern
obtain
use
human
intestin
epitheli
cell
line
express
endogen
cathepsin
fig
contrast
alon
fulli
block
ebola
pseudoviru
infect
camostat
impact
viral
infect
fig
middl
panel
final
treatment
cell
camostat
impact
vsvg
driven
viral
entri
fig
right
panel
known
independ
cystein
serin
proteas
activ
result
indic
serin
cystein
proteas
activ
viral
entri
expect
ebovgp
exclus
reli
cystein
proteas
activ
next
synthes
seri
analog
explor
antivir
activ
vinylsulfoneclass
proteas
inhibitor
tabl
given
piperazin
ring
basic
pka
conjug
acid
consid
compound
might
accumul
acid
lysosom
endosom
compart
target
proteas
ctsl
ctsb
abund
explor
notion
gener
evalu
structureact
trend
synthes
new
vinylsulfon
analog
substitu
piperazin
ring
nitrogen
atom
modifi
systemat
major
analog
tabl
retain
basic
piperazin
ring
nphenyl
analog
weakli
basic
pka
conjug
acid
thu
neutral
physiolog
ph
would
expect
exhibit
lysosomotrop
behavior
nearli
new
analog
possess
potenc
compar
superior
sarscov
ebov
tabl
potent
analog
sarscov
ic
nm
ebov
ic
nm
sarscov
ic
nm
ebov
ic
nm
sarscov
ic
nm
ebov
ic
nm
flavivirida
ssrna
ic
inhibitori
concentr
valu
concentr
requir
inhibit
infect
pseudotyp
virus
cell
determin
dose
respons
curv
envelop
apart
nipah
junin
use
make
hivbas
pseudotyp
target
cell
express
vero
cell
pretreat
serial
dilut
expos
viru
vsvbase
pseudotyp
made
transfect
cell
nipah
f
g
plasmid
junin
envelop
transduc
vsvdg
gfp
g
progeni
viru
collect
titer
target
cell
nonlinear
regress
analysi
base
sigmoid
dose
respons
equat
appli
percent
inhibit
concentr
data
data
shown
mean
triplic
measur
standard
deviat
valu
repres
least
two
independ
experi
particular
note
structureact
data
weakli
basic
analog
less
potent
basic
protonat
vinylsulfon
analog
tabl
reduc
potenc
like
relat
size
phenyl
substitu
sinc
even
larger
biaryl
substitu
known
well
toler
cathepsinl
like
proteas
cruzain
beaulieu
et
al
also
consist
interpret
find
bulki
tertbutyl
cyclopentyl
group
toler
analog
like
therefor
like
explan
weak
base
analog
expect
proton
physiolog
ph
accumul
lysosom
extent
basic
analog
convers
basic
analog
accumul
acid
endosom
compart
target
cystein
proteas
ctsl
ctsb
locat
verifi
antivir
effect
three
effici
drug
candid
inhibit
assay
carri
two
strain
urbani
replic
compet
sarscov
use
two
separ
readout
replic
summar
si
cc
ic
rang
inhibit
strain
thu
compound
identifi
ideal
tool
determin
whether
cystein
serin
proteas
promot
sarscov
spread
host
pharmacokinet
bioavail
male
femal
spraguedawley
rat
determin
follow
singl
iv
po
dose
administr
data
shown
demonstr
similar
profil
jacobsen
et
al
initi
experi
antivir
efficaci
lowdos
mgkg
examin
lethal
sarscov
mous
model
day
et
al
trend
toward
protect
statist
signific
reduct
mortal
diseas
sever
data
shown
experi
therefor
repeat
higher
dose
cystein
proteas
inhibitor
mgkg
either
alon
combin
serin
proteas
inhibitor
camostat
mgkg
fig
alon
effect
vehicl
treat
control
fig
contrast
camostat
effect
protect
mice
death
due
lethal
infect
sarscov
surviv
rate
combin
class
inhibitor
significantli
improv
surviv
versu
camostat
alon
thu
sarscov
depend
serin
proteas
activ
viral
spread
vivo
viral
entri
multistep
process
attract
target
antivir
zhou
simmon
fact
dispar
pathogen
virus
sarscov
ebov
niv
util
common
host
factor
entri
ctsl
suggest
inhibitor
cathepsin
might
broad
applic
cystein
proteas
prove
druggabl
target
inhibitor
gener
low
toxic
screen
librari
druglik
compound
establish
activ
ctsl
ctsb
activ
sarscov
filovirus
includ
ebov
describ
confirm
proteas
inhibitor
relat
compound
broadspectrum
antivir
drug
candid
target
viral
entri
number
addit
vinylsulfon
analog
synthes
exhibit
enhanc
potenc
compar
notabl
potent
antivir
activ
correl
presenc
basic
piperazin
ring
posit
find
consist
accumul
endosom
acid
compart
target
cystein
proteas
requir
viral
entri
locat
vinylsulfon
describ
herein
broadli
activ
viral
entri
three
viral
famili
corona
filoand
paramyxovirus
well
toler
vivo
barr
et
al
notion
coronavirus
includ
sarscov
use
cathepsindepend
endosom
pathway
direct
cellsurfac
serin
proteasemedi
pathway
entri
simmon
et
al
support
find
combin
camostat
superior
either
compound
alon
contrast
ebov
infect
effect
inhibit
camostat
unidentifi
addit
proteas
report
mediat
infect
filovirus
marv
gnirss
fig
effect
per
os
administ
andor
camostat
surviv
balbc
mice
infect
lethal
sarscov
ten
mice
per
group
dose
twice
day
oral
gavag
andor
camostat
diluent
alon
steril
water
day
begin
h
prior
infect
pfu
mouseadapt
sarscov
et
al
sudv
misasi
et
al
effici
inhibit
vinylsulfon
analog
suggest
unidentifi
proteas
cystein
proteas
relat
ctsb
l
activ
niv
hev
appear
fulli
depend
ctsl
andor
ctsb
pager
et
al
diederich
et
al
diederich
et
al
thu
vinylsulfon
promis
antivir
lead
compound
optim
potent
inhibitor
two
import
group
pathogen
emerg
virus
includ
ebov
previou
report
show
compound
analog
satisfactori
safeti
pharmacokinet
profil
rodent
dog
primat
abdulla
et
al
fact
vinylsulfon
irrevers
highli
select
cystein
proteas
inhibitor
appear
liabil
least
use
short
cours
antivir
inde
case
filovirus
lack
target
select
like
boon
increas
effect
also
inhibit
secondari
proteas
gnirss
et
al
misasi
et
al
avail
novel
highli
potent
larg
nontox
cystein
proteas
inhibitor
afford
opportun
assess
whether
activ
cystein
serin
proteas
requir
viral
spread
vivo
mous
model
lethal
sarscov
infect
employ
notabl
inhibit
serin
proteas
mitig
sarscov
pathogenesi
vivo
thu
futur
develop
anticoronaviru
therapeut
focu
inhibit
serin
rather
cystein
proteas
camostat
excel
start
candid
inde
japan
camostat
use
clinic
particularli
treat
chronic
pancreat
ikeda
et
al
sai
et
al
reason
safeti
profil
fiopan
tablet
result
show
target
viral
entri
specif
endosom
proteolysi
step
entri
attract
strategi
discov
new
antivir
agent
particularli
filovirus
like
ebov
paramyxovirus
although
endosom
cellsurfac
proteas
facilit
coronaviru
entri
cultur
cell
activ
serin
proteas
requir
viral
spread
infect
host
nevertheless
highli
potent
cystein
proteas
inhibitor
identifi
might
excel
start
point
develop
highli
effect
inhibitor
ebola
viru
paramyxoviru
entri
constitut
excel
research
tool
dissect
molecular
mechan
viral
entri
